{"Drugs":{"Drug":{"Id":11057,"DrugType":{"Type":"Small molecule therapeutic"},"DevelopmentStatusCurrent":{"Row":[{"Company":{"@id":"28355","$":"GlaxoSmithKline plc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"DX","@sortorder":"4","$":"Discontinued"},"Indication":{"@id":"119","$":"Epilepsy"},"StatusDate":"2003-12-08T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"516472"}},{"Company":{"@id":"28355","$":"GlaxoSmithKline plc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"DX","@sortorder":"4","$":"Discontinued"},"Indication":{"@id":"210","$":"Migraine"},"StatusDate":"2003-12-08T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"516472"}}]},"DevelopmentStatusHistoric":{"Row":[{"Company":{"@id":"28355","$":"GlaxoSmithKline plc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"119","$":"Epilepsy"},"StatusDate":"2001-02-28T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"399771"}},{"Company":{"@id":"28355","$":"GlaxoSmithKline plc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"210","$":"Migraine"},"StatusDate":"2001-11-01T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"426830"}},{"Company":{"@id":"19962","$":"SmithKline Beecham plc"},"Country":{"@id":"US","$":"US"},"DevelopmentStatus":{"@id":"C2","@sortorder":"11","$":"Phase 2 Clinical"},"Indication":{"@id":"119","$":"Epilepsy"},"StatusDate":"1998-01-29T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"243338"}},{"Company":{"@id":"19962","$":"SmithKline Beecham plc"},"Country":{"@id":"GB","$":"UK"},"DevelopmentStatus":{"@id":"C1","@sortorder":"10","$":"Phase 1 Clinical"},"Indication":{"@id":"119","$":"Epilepsy"},"StatusDate":"1995-10-03T00:00:00Z","SourceLink":{"@type":"CORPORATE","@id":"188452"}}]}}}}